GlassScriptPhysician profile
Jennifer Wang
NPI 1962897561
$6,890.26
in general payments reported to CMS, 2019-2025
7 companies · $6,537 in 2025
The $6,537 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2023: $13.67 · 2025: $6,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,900 · Travel and Lodging: $1,096 · Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,900.00 |
| Travel and Lodging | $1,095.58 |
| Food and Beverage | $555.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $4,019.64 | 2025 | Livmarli |
| Madrigal Pharmaceuticals | $2,517.40 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.34 | 2019 | |
| Exelixis INC. | $112.76 | 2019 | |
| Janssen Biotech, INC. | $90.95 | 2019 | |
| Dova Pharmaceuticals | $19.50 | 2019 | |
| Boston Scientific Corporation | $13.67 | 2023 | Exalt Model D |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.